

Synopsis of GYNECOLOGIC ONCOLOGY

Third Edition

C. PAUL MORROW

DUANE E. TOWNSEND

1990年3月21日



Synopsis of GYNECOLOGIC ONCOLOGY

Third Edition

C. PAUL MORROW, M.D.

Professor of Gynecology
Director of Gynecologic Oncology
University of Southern California School of Medicine
Los Angeles, California

DUANE E. TOWNSEND, M.D.

Clinical Professor
Department of Obstetrics and Gynecology
University of Southern California at Davis
Sacramento, California

With Contributions By:

JOHN A. BLESSING, Ph.D.

JOHN E. BYFIELD, M.D., Ph.D.

CONLEY G. LACEY, M.D.

DOUGLAS J. MARCHANT, M.D.

MALCOLM S. MITCHELL, M.D.

J. TATE THIGPEN, M.D.

A WILEY MEDICAL PUBLICATION

JOHN WILEY & SONS

New York • Chichester • Brisbane • Toronto • Singapore



馆藏专用章



SYNOPSIS OF GYNECOLOGIC ONCOLOGY

Third Edition



C. PAUL MORROW, M.D.
Professor of Gynecology
Director of Gynecologic Oncology
University of Southern California School of Medicine
Los Angeles, California

DUANE E. TOWNSEND, M.D.

Copyright © 1987 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

Library of Congress Cataloging in Publication Data:

Morrow, C. Paul, 1935—

Synopsis of gynecologic oncology.

(A Wiley medical publication)

- Includes bibliographies and index.

I. Generative organs, Female—Cancer.

I. Townsend, Duane E. II. Title. III. Series.

[DNLM: 1. Genital Neoplasms, Female. WP 145 M883s]

RC280.G5M67 1987

616.99'465

87-2112

ISBN 0-471-83749-0

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

Contributors


JOHN A. BLESSING, Ph.D.
Director of Statistics
Gynecologic Oncology Group
Roswell Park Memorial Institute
Buffalo, New York

JOHN E. BYFIELD, M.D., Ph.D.
Radiation Therapist
Daniel Freeman Hospital
Los Angeles, California
Formerly, Professor and Chief of
Radiation Oncology
University of California at San Diego
San Diego, California

CONLEY G. LACEY, M.D.
Professor of Clinical Obstetrics and
Gynecology
University of California at San Francisco
San Francisco, California

DOUGLAS J. MARCHANT, M.D.
Professor of Obstetrics and Gynecology
Professor of Surgery
Tufts University School of Medicine
Boston, Massachusetts

MALCOLM S. MITCHELL, M.D.
Professor of Medicine and Microbiology
University of Southern California School
of Medicine
Los Angeles, California



J. TATE THIGPEN, M.D.
Professor of Medicine
Director, Division of Medical Oncology
University of Mississippi Medical School
Jackson, Mississippi

Preface

This book is intended to be a complete guide to the practice of gynecologic oncology for the physician in training, the general gynecologist, and the cancer specialist. The contents integrate the essential clinical characteristics of the various gynecologic tumors (symptoms, physical findings, epidemiology) with detailed, explicit information concerning their diagnosis, treatment, and outcome. The scope has been expanded in this, the third edition, by incorporating unusual malignant tumors, benign tumors, and related conditions such as genital warts and the vulvar dystrophies. In addition, chapters have been added on breast diseases (Dr. Marchant) and medical statistics (Dr. Blessing). The section on chemotherapy has been completely rewritten by J. Tate Thigpen, M.D., and Malcolm S. Mitchell, M.D., has contributed a new chapter on immunology.

There has been a reordering of the chapters for organizational purposes. Every section has been revised on the basis of a detailed review of the literature and changes in clinical practice since the last edition. Thus, the third edition has undergone major revisions in order to broaden its scope and update its information. The breadth of coverage, we believe, makes this volume uniquely qualified to serve as a basic textbook as well as a reference work for clinical practice.

The volume and quality of new information in the discipline of gynecologic oncology continue to increase at a formidable pace. It is clearly beyond the capacity of a single individual to master. All of us, then, must rely upon the work, advice, and experience of others. We have solicited contributions from experts in several important areas: John A. Blessing, Ph.D., in medical statistics; John E. Byfield, M.D., Ph.D., and Conley G. Lacey, M.D., in radiation therapy; Douglas J. Marchant, M.D., in diseases of the breast; Malcolm S. Mitchell, M.D., in the field of immunology; and J. Tate Thigpen, M.D., in chemotherapy. For assistance in reviewing portions of the manuscript, we wish to thank our clinical fellows, Joséé Dubuc-Lissoir and Fredrick J. Montz. Rogerio A. Lobo, M.D., provided invaluable assistance with the endocrinologic aspects of this book. We are especially indebted to John B. Schlaerth, M.D., friend and associate of many years, who is an unfailing source of information, advice, and support. We wish to acknowledge the secretarial assistance of Sylvia P. Rivera and Joann Little. Finally, we give our enduring thanks to Dianna Livingstone, who singlehandedly organized and put onto computer disks, according to the publisher's specifications, the entire manuscript for this book.

C. PAUL MORROW, M.D.
DUANE E. TOWNSEND, M.D.

Contents

1. Premalignant and Related Disorders of the Lower Genital Tract 1

- Human Papilloma Virus Infections, 1
 - General Considerations, 1
 - Vulvar Condylomas, 1
 - Vaginal Condylomas, 2
 - Cervical Condylomas, 3
- Premalignant Lesions of the Vulva, 3
- Vulvar Dysmorphies, 3
- Vulvar Intraepithelial Neoplasia (VIN), 8
- Vaginal Intraepithelial Neoplasia (VAIN), 14
 - Etiology, 14
- Cervical Intraepithelial Neoplasia (CIN), 17
 - Etiology, 19
 - Detection of CIN, 19
 - The Class II or Atypical Pap Smear, 19
 - Evaluation of CIN, 20
 - Management of CIN, 22
- Colposcopy, 28
 - Normal Transformation Zone, 29
 - Colposcopically Overt Carcinoma, 31
 - Satisfactory or Unsatisfactory Examination, 31
 - Other Colposcopic Findings, 36
 - Other Applications of Colposcopy, 36
- References, 38

2. Vaginal Adenosis, Adenocarcinoma, and Diethylstilbestrol 45

- Evaluation and Management of the DES-Exposed Patient, 45
- Natural History of DES Changes, 46
- Clear Cell Adenocarcinoma, 49
- Squamous Cell Neoplasia, 53
- References, 53

3. Tumors of the Vulva

57

- Benign Tumors of the Vulva, 57
 - Nonneoplastic Tumors, 57
 - Benign Vulvar Neoplasms, 58
 - Pigmented Lesions of the Vulva, 59
 - Erosions and Ulcers of the Vulva, 60
- Premalignant and Related Disorders of the Vulva: Condylomas, Vulvar Dystrophies, Vulvar Intraepithelial Neoplasia (See Chapter 1), 60
- Malignant Tumors of the Vulva, 60
 - Squamous Carcinoma, 61
 - Variants of Squamous Cell Carcinoma, 77
 - Other Vulvar Malignancies, 78
- References, 84

4. Tumors of the Vagina

91

- Benign Tumors of the Vagina, 91
- Premalignant and Related Disorders of the Vagina: Condylomas and Vaginal Intraepithelial Neoplasia (See Chapter 1), 92
- Malignant Tumors of the Vagina, 92
 - Squamous Carcinoma, 92
 - Other Vaginal Malignancies, 96
- References, 99

5. Tumors of the Cervix

103

- Benign Tumors of the Cervix, 103
 - Endocervical Polyps, 103
 - Capillary Hemangioma, 103
 - Microglandular Hyperplasia, 103
- Premalignant and Related Disorders of the Cervix: Condylomas and Cervical Intraepithelial Neoplasia (See Chapter 1), 104
- Malignant Tumors of the Cervix—Squamous Carcinoma, 104
 - Epidemiology, 104
 - Etiology, 105
 - Cervical Cancer Screening, 107
 - Clinical Features, 108
 - Pathophysiology, 112
 - Prognostic Factors, 114
 - Staging and Evaluation, 118
 - Treatment, 122
 - Special Treatment Categories, 131
 - Follow-up and Recurrence, 137
- Other Malignant Tumors of the Cervix, 140
 - Verrucous Carcinoma, 140
 - Adenocarcinomas, 141
 - Mixed Carcinomas, 145
 - Apudomas, 146
 - Sarcomas and Lymphomas, 146
- References, 146

6. Tumors of the Endometrium 159**Benign and Premalignant Tumors, 159**

The Endometrial Hyperplasias, 159

Benign Endometrial Polyps, 163

Endometrial Metaplasia, 164

Endometrial Carcinoma, 164

Epidemiology, 164

Endometrial Cancer Screening, 168

Clinical Features, 169

Pathology, 173

Clinical Staging and Evaluation, 174

Surgical-Pathologic Staging, 176

Treatment, 178

Recurrence, 185

Special Treatment Categories, 190

Other Endometrial Carcinomas, 194

Adenosquamous Carcinoma, 194

Papillary Serous Carcinoma, 195

Clear Cell Carcinoma, 195

Squamous Cell Carcinoma, 196

References, 196

7. Uterine Sarcomas and Related Tumors 207

Classification, 207

Myometrial Sarcomas and Related Tumors, 208

Benign and Borderline Malignant Smooth Muscle Tumors, 208

Leiomyosarcoma, 209

Endometrial Sarcomas and Related Tumors, 212

Pure Tumors of Endometrial Stroma, 212

Mixed Tumors of the Endometrium, 215

Pure Heterologous Tumors, 221

Miscellaneous Soft Tissue Tumors of the Uterus, 221

Hemangiopericytoma, 221

Lipomatous Tumors (Benign Mixed Mesodermal Tumors), 222

Other Tumors, 222

References, 223

8. Tumors of the Fallopian Tube 227

Benign Tumors and Tumor-Like Conditions, 227

Malignant Tumors of the Fallopian Tube, 227

Adenocarcinoma, 227

Sarcomas of the Fallopian Tube, 229

References, 230

9. Tumors of the Ovary: General Considerations; Classification; the Adnexal Mass	231
General Considerations, 231	
Epidemiology, 231	
Etiology, 232	
Familial Ovarian Carcinoma, 234	
Screening for Ovarian Neoplasia, 235	
Preventing Ovarian Cancer, 236	
Classification of Ovarian Tumors, 236	
The Adnexal Mass, 238	
Symptoms, 239	
Physical Findings, 241	
Preoperative Evaluation, 243	
Operative Management, 249	
References, 253	
10. Tumors of the Ovary: Neoplasms Derived from Coelomic Epithelium	257
Benign Epithelial Neoplasms, 257	
Characteristics of the Histologic Subtypes, 257	
Management of Benign Epithelial Tumors, 262	
Borderline Epithelial Tumors, 262	
Characteristics of Histologic Subtypes, 263	
Treatment of Borderline Ovarian Malignancies, 268	
Obviously Malignant Epithelial Neoplasms, 268	
Characteristics of Histologic Subtypes, 268	
Pathophysiology, 275	
Prognostic Factors, 278	
Management of Ovarian Carcinoma, 281	
Special Management Problems, 290	
Reproductive Conservation, 290	
Serous Effusions, 291	
Ovarian Tumors in Pregnancy, 292	
Ovarian Tumors in Children, 292	
References, 295	
11. Tumors of the Ovary: Sex Cord Stromal Tumors and Germ Cell Tumors	305
Sex Cord Stromal Neoplasms, 305	
Granulosa-Stromal Cell Tumors, 306	
Sertoli-Leydig Cell Tumors (Androblastomas), 309	
Evaluation of Androgen Excess, 312	
Management of Ovarian Stromal Tumors, 314	
Germ Cell Tumors, 314	
Teratomas, 315	
Dysgerminoma, 320	
Endodermal Sinus Tumor (EST), 322	

- Embryonal Carcinoma, 324
- Choriocarcinoma, 324
- Polyembryoma, 324
- Mixed Germ Cell Tumors, 325
- Gonadoblastoma, 325
- Management of Germ Cell Tumors, 325
- References, 329

12. Tumors of the Ovary: Soft Tissue and Secondary (Metastatic) Tumors; Tumor-Like Conditions 335

- Soft Tissue Tumors Not Specific to the Ovary, 335
 - Fibroma, 335
 - Lymphoma, 336
- Tumors Metastatic to the Ovary, 336
- Tumor-Like Conditions of the Ovary, 337
 - Pregnancy Luteoma, 337
 - Ovarian Hyperthecosis, 337
 - Massive Ovarian Edema, 338
 - Solitary Functional Cysts, 339
 - Polycystic Ovaries, 339
 - Theca-Lutein Cysts and Multiple Corpora Lutea, 340
 - Endometriotic Cysts (Endometriomas), 340
 - Germinal Inclusion Cysts, 341
 - Simple Cysts, 341
 - Parovarian Cysts, 341
- References, 342

13. Tumors of the Placental Trophoblast 345

- Normal Trophoblast, 345
- Hydatidiform (Hydatid) Mole, 346
 - Epidemiology, 346
 - Classification of Molar Pregnancies, 348
 - Cytogenetics, 349
 - Diagnosis, 351
 - Nonneoplastic Complications, 354
 - Management of Molar Pregnancy, 355
- Invasive Mole, 357
- Choriocarcinoma, 357
- Placental Site Trophoblastic Tumor, 359
- Management of GTN, 360
 - Human Chorionic Gonadotropin Assay, 360
 - Postmolar Pregnancy Surveillance, 365
 - Abnormal Postmolar hCG Regression, 369
 - Nonmetastatic GTN (Stage I), 371
 - Metastatic GTN (Stages II–IV), 374
- Pregnancy after Chemotherapy for GTN, 380
- References, 382

14. Diseases of the Breast

by Douglas J. Marchant

- General Considerations, 389
 - Development of Breast Tissue, 389
 - Physiologic Alterations, 390
- Breast Cancer, 393
 - Risk Factors and Epidemiology, 393
 - Diagnosis, 394
 - Treatment, 403
 - Postoperative Management, 407
- References, 407

389

15. Chemotherapy

by J. Tate Thigpen

- General Principles, 409
 - Mechanisms of Cytotoxicity, 409
 - Factors Influencing the Response, 411
 - Mechanisms of Resistance, 412
- Current Practice, 413
 - Combination Chemotherapy, 413
 - Drug Schedule, 414
 - Adjuvant Chemotherapy, 414
 - Special Cases, 414
 - Summary, 416
- Drug Development, 417
 - Clinical Trials, 417
- Specific Drugs, 419
 - Alkylating Agents, 419
 - Antimetabolites, 427
 - Plant Alkaloids, 431
 - Other Useful Agents, 433
- Chemotherapy of Specific Neoplasms, 433
 - Cancer of the Ovary, 434
 - Cancer of the Uterine Cervix, 439
 - Cancer of the Endometrium, 442
 - Other Neoplasms, 445
- Conclusion, 447
- References, 447

409

16. Principles of Radiation Therapy

by John E. Byfield and Conley G. Lacey

- Introduction to Radiation Oncology, 459
- Radiation Physics, 460
 - Structure of Matter, 460
 - Origins of Natural Radioactivity: Radioactive Decay, 460
 - Physical Absorption of Ionizing Radiation, 462
 - Inverse Square Law, 463

459

External Beam Radiation Treatment Instrumentation, 464

Radiocobalt, 465

Electrical Treatment Units, 467

Common Terms Used in Therapeutic Radiology, 468

Experimental Instruments, 469

Skin and Bone Sparing, 469

Treatment Planning, 469

Introduction to Radiation Biology, 470

DNA Damage, 470

Initial Radiation Chemistry of X-Ray Damage, 470

Relative Biologic Effectiveness (RBE), 472

Postradiation Repair and Cell Survival, 472

Oxygen Effect, 478

Early Adverse Effects: Cellular Basis, 480

Late Adverse Effects (Complications), 481

Clinical Implications of Radiation Biology, 482

Tumor versus Normal Cell Repopulation Kinetics, 483

Time-Dose Fractionation, 485 •

Radiation Therapy for Cervical Carcinoma, 487

Choice of Modality, 487

Treatment Dose and Dosimetry, 487

Treatment Volume, 492

Intracavitary Treatment Applicators, 492

Sequence of External and Intracavitary Therapy, 496

Newer Approaches to Radiation Therapy for Cervical Cancer, 499

Radiation Therapy for Endometrial Carcinoma, 502

Stage I Carcinomas, 502

Stage II Carcinomas, 503

Stage III Carcinomas, 503

Radiation Therapy for Ovarian Carcinoma, 504

External Beam Therapy, 504

Intraperitoneal Radioactive Colloids, 505

Adverse Effects of Radiation, 508

Pathology, 508

Acute Radiation Reactions, 509

Delayed Radiation Reactions, 509

Conclusions, 515

References, 516

17. Immunology and Immunotherapy of Gynecologic Cancers**521***by Malcolm S. Mitchell*

Principles of Tumor Immunology, 521

Tumor Antigens, 521

The Immune Response to Tumor Antigens, 523

Immunologic Surveillance, 524

Escape of Established Tumors from Immunologic Rejection, 525

Immunotherapy, 525

Immunology of Gynecologic Cancers, 527

Tumor Antigens, 527

Antibody-Mediated Immunity, 528	
Cell-Mediated Immunity, 528	
Immunotherapy of Gynecologic Cancers, 529	
Nonspecific Active Immunotherapy, 529	
Specific Active Immunotherapy, 530	
Summary and Conclusions, 531	
References, 531	

18. Principles of Statistics 535

by John A. Blessing

Introduction, 535	
Probability, 535	
Binomial Distribution, 536	
Normal Distribution, 536	
Statistical Topics, 539	
Sampling Theory, 539	
Confidence Intervals, 541	
Estimation, 543	
Hypothesis Testing, 543	
Clinical Trials Applications, 545	
Phase II Studies, 546	
Phase III Studies, 547	
Contingency Tables, 550	
Life Tables, 551	
P Values, 553	
Other Topics, 553	
Conclusions, 554	
References, 555	

19. Staging and Classification 557

Classification and Staging of Malignant Tumors in the Female Pelvis, 557	
General Rules (FIGO, 1971 and 1985) for Clinical Classification and Staging, 557	
Carcinoma of the Uterus and Vagina, 557	
Carcinoma of the Cervix, 558	
Carcinoma of the Corpus, 560	
Carcinoma of the Vagina, 562	
Carcinoma of the Vulva, 563	
Carcinoma of the Ovary, 563	

INDEX

1

Premalignant and Related Disorders of the Lower Genital Tract

HUMAN PAPILLOMA VIRUS INFECTIONS

General Considerations

Also known as anogenital or venereal warts, condylomata acuminata are caused by several highly infectious, sexually transmitted serotypes of the human papilloma virus (HPV). At least four distinct benign epithelial lesions of the female genital tract attributable to HPV infection have been described: (1) the typical verrucous or papillary acuminate wart, (2) the flat or intraepithelial condyloma, (3) the inverted condyloma, and (4) the giant condyloma. Multiple sites of involvement are common. The presence of extensive warts suggests an immune suppressed state such as pregnancy, organ transplantation, or an immune deficiency disease.

During the past two decades the prevalence of anogenital warts has reached near-epidemic proportions. The accumulating evidence that certain HPV serotypes can be oncogenic in humans has intensified the general concern regarding the prevalence of HPV infections. HPV strains 16 and 18 are commonly associated with invasive cervical carcinoma, as well as the more severe aneuploid dysplasias, while strains 6 and 11 occur almost exclusively in the lesser dysplasias and condylomas that have a polyploid DNA distribution. Since aneuploidy confers a substantial risk of progression, and since polyploidy is associated with spontaneous regression, it appears that the oncogenic risk of HPV infections is, among other things, dependent upon the infecting viral strain or serotype (Fu et al, 1981; Crum et al, 1982a, 1984b; Rastkar et al, 1982; Stanbridge and Butler, 1983; Reid et al, 1984b; Winkler et al, 1984). The evidence that HPV is related to malignant and premalignant squamous neoplasia of the lower genital tract is further described in Chapter 5.

Vulvar Condylomas

The spiculated or filiform perineal warts are managed initially with weekly 25% podophyllin or trichloroacetic acid (TCA) applications two to three times per week. If the warts fail to regress, biopsy 4–6 weeks after the last treatment is indicated. With an incubation period of 4–12 weeks or longer, new lesions may develop, however, and these should not be taken as evidence of treatment failure. Management of the typical case also requires treatment for associated infections, especially trichomonas. Extensive or refractory lesions are best treated by laser therapy. The giant condylomas (Fig. 1.1) do not respond to podophyllin or TCA therapy. Excision with a knife, laser, or wire loop cautery is recommended after adequate biopsy has excluded the presence of carcinoma. Intramuscular and intralesional



Figure 1.1. Giant condyloma. These cauliflower-like growths had been present for over 30 years. When removed from a patient 65 years of age, foci of severe squamous dysplasia were present. This form of condyloma does not respond to medical therapy. (From Morrow, 1987. Reproduced with permission of Churchill Livingstone, London.)

interferon therapy appears to be effective in clearing 30–50% of resistant genital warts (Eron et al, 1986; Gall et al, 1986). Induration at the base is very suggestive of malignancy.

Flat condylomas of the vulva closely resemble the dysplastic lesions of Bowenoid papulosis. Except for focal involvement, the treatment of choice is laser vaporization. This can often be accomplished in the office setting under local anesthesia. The lesions themselves are treated to the level of the dermal papillae. A 5-mm zone of surface epithelium surrounding each lesion, or all intervening epithelium in cases of extensive disease (Ferenczy et al, 1985), is treated by the low power density (350–450 W/cm²) brush technique to minimize scarring (Reid, 1985). This is especially important when treating the anal canal or urethra. Laser therapy also provides a safe and effective means of treating selected anogenital condylomas complicating pregnancy (Ferenczy, 1984b). For the first month after therapy intercourse is interdicted. Thereafter, condoms should be used until both partners are clear of lesions for at least 6 weeks.

Vaginal Condylomas

Condylomata acuminata of the vagina may be isolated, but most are associated with cervical and/or vulvar condylomas, with which they share many common features. Their occurrence in conjunction with dysplasia is frequent. Vaginal condylomas of the spiculated variety generally present with vaginal discharge and pruritus, while flat (intraepithelial) condylomas are often detected only by routine cytology.

Evaluation begins with a careful gross examination of the lower genital tract and perineum followed by colposcopy, Lugol's staining, and directed biopsy of the vagina and cervix. TCA treatment of the fresh, spiculated condylomas can be successful if the lesions are not extensive, but this treatment is ineffective against the flat wart. For this type of condyloma, as well as the resistant or extensive papillary variety, intravaginal 5-fluorouracil (5-FU) or laser vaporization is recommended. The former is more cost effective but is not applicable to pregnant women (Ferenczy, 1984a). Laser treatment of multiple vaginal condylomas requires the use of the brush technique to eradicate the virus-

containing, normal-appearing epithelium between the warty lesions. Precautions against reinfection, as described for cervical condylomas, are necessary.

Cervical Condylomas

It is common knowledge that the cervix is an unusual site for the typical spiculated venereal wart. Consequently, the high frequency of cervical HPV infection was not appreciated until the late 1970s when Meisels and associates described the flat (intraepithelial) condyloma (Meisels and Fortin, 1976; Meisels et al, 1977; Meisels and Morin, 1981). The inconspicuous epithelial hyperplasia closely resembles squamous dysplasia clinically, colposcopically, cytologically, and histologically. Thus, it is not surprising that its true nature remained unknown until the technology to identify the HPV virus became available. These condylomatous lesions were previously classified as dysplasias when cytologic atypia was prominent and as inflammatory when atypia was absent or inconspicuous.

The widespread prevalence of cervical HPV infections has now been abundantly documented. In retrospective studies, about 75% of cervical intraepithelial neoplasia (CIN) I and 50% of CIN II lesions are reclassified as flat condylomas. Pap smear screening of the general population indicates a 1.5% prevalence rate of genital HPV infection, approximately three times that of squamous dysplasia. More than half of the cases of anogenital condylomas in women are now accounted for by cervical lesions (Meisels et al, 1982).

Diagnosis

The flat condylomas develop within the transformation zone. They are not usually visible until acetic acid is applied, after which they turn white. Typical colposcopic features include a micropapillary contour, inconspicuous vascular pattern, feathered margins, satellite lesions, and a shiny snow white color (Reid and Scalzi, 1985). Biopsy is required, however, to document the nature of the lesion. An intimate admixture of flat condyloma and bona fide dysplasia is common.

Histologically, the distinctive feature of the intraepithelial condyloma is koilocytosis (Fig. 1.2; Crum et al, 1982b). Crum and Levine (1984) have reported that HPV infection of immature squamous metaplasia does not produce koilocytic changes. In this situation, the pathologic diagnosis is likely to be atypical immature metaplasia.

Management

Although many cervical condylomas regress spontaneously, it is generally recommended that even the milder forms be treated because there is no practical way to determine which are potentially malignant, that is, those that are aneuploid or caused by HPV-16 and HPV-18. Furthermore, the lesions are considered highly infectious. Concurrent involvement of the vagina and/or vulva is common.

The preferred treatment for cervical condylomas whether flat, inverted, or papillary, is laser vaporization. The entire transformation zone is treated to a depth of 5–7 mm, with a lateral margin of 5 mm (Baggish, 1985). The sexual partner should also be examined, since reinfection is a frequent cause of treatment failure. Condylomas are reportedly found in 50–75% of male partners if colposcopic magnification is used (Levine et al, 1984; Sedlacek et al, 1986). Posttreatment precautions against reinfection are recommended. Cure rates with a single treatment have been somewhat poorer than those of dysplasia.

PREMALIGNANT LESIONS OF THE VULVA

Vulvar Dysmorphies

The chronic vulvar dermatoses have now been sorted out on a histopathologic basis providing the clinician with a far simpler, more useful working classification than that based on




Figure 1.2. Cervical intraepithelial condyloma. Characteristic vacuolization and ballooning of the upper cell layer is termed *koilocytosis*. In the parabasal cells there is nuclear enlargement without abnormal mitoses. (Courtesy of Gerrit d'Ablaing, M.D.)

the gross morphology of these lesions. Instead of the red/white, keratinized/nonkeratinized grouping, the more specific diagnostic categories of lichen sclerosus (et atrophicus, LSA), hyperplastic dystrophy, and mixed forms, all with or without atypia [vulvar intraepithelial neoplasia (VIN) or dysplasia] are determined by tissue biopsy. The treatment is based on the specific histologic diagnosis and the presence or absence of dysplasia. In general when VIN is present, ablative therapy is indicated, while medical therapy predominates in the absence of dysplasia. The goals of treatment are to relieve symptoms, to prevent the development of carcinoma, and to restore tissue normalcy. In most instances, these goals can be achieved only in part.

Lichen Sclerosus (LSA)

Etiology Lavery and Pinkerton (1983) have proposed that the hyperplastic, atrophic (LSA) and mixed dystrophies are phases of a single disease process most likely of autoimmune origin. The association of LSA with autoimmune phenomena is well documented. Various authors have reported an increased incidence of achlorhydria, vitiligo, diabetes, thyroiditis, pernicious anemia, antibodies to gastric parietal cells, and intrinsic factor in patients with LSA (Harrington and Dunsmore, 1981). Meyrick-Thomas et al (1982) found that 75% of their LSA study group had at least one autoantibody and 20% had evidence of an autoimmune disease. Fifteen instances of familial LSA have been documented with recent evidence suggesting an HLA linkage (Friedrich and MacLaren, 1984).

Lavery and Pinkerton have proposed that the association of LSA with achlorhydria suggests that LSA may result from abnormal levels of gastrointestinal hormones, especially urogastrone. This peptide in excess inhibits the production of hydrochloric acid (HCL) while stimulating the production of epidermal growth factor. The latter, it is postulated, causes hypertrophy of the vulvar skin accompanied by increased levels of somatostatin, a